Accretion Nutraveda IPO Day 1: Weak Subscription, Listing Set for Feb 4

The Accretion Nutraveda IPO, which opened for subscription on 28 January 2026, saw a very weak investor response on its first day of bidding, with subscription levels reported at only about 0.01 times as of midday trading.

Here’s a clear summary of key details and developments for the IPO:

IPO and Issue Details
• Opening date: 28 January 2026
• Closing date: 30 January 2026
• Price band: ₹122 – ₹129 per share
• Lot size: 1,000 shares
• Minimum investment: Around ₹2,44,000 – ₹2,58,000 depending on how many lots applied for at the top of the band
• Issue size: Around ₹24.77 crore (fresh issue)
• Listing: Shares are set to list on the BSE SME platform.

Subscription Status (Day 1)
• The IPO was subscribed only about 0.01 times on 28 January 2026, indicating very low demand from investors on the first day of bidding.

IPO Timeline After Subscription
• Basis of allotment: Expected on 2 February 2026
• Refunds initiation: Around 3 February 2026
• Shares credited to Demat accounts: Around 3 February 2026
• Tentative listing date: 4 February 2026 on BSE SME.

Company Background
Accretion Nutraveda is a healthcare-focused contract development and manufacturing organization (CDMO) that specialises in nutraceuticals and Ayurvedic products, including tablets, capsules, oral liquids and powders across a range of care segments such as digestive, cardio, skin & hair, baby care, and more.

Investors will be watching how the subscription figures evolve over the remaining two days of the IPO and whether sentiment improves ahead of the allotment and listing.